STAT+: ‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period
STAT
NOVEMBER 28, 2022
billion from 2015 to 2020 — or nearly 5% of the $30.2 The provision is known as skinny labeling , which refers to a move by a company that seeks regulatory approval to market a generic or biosimilar medicine for a specific use, but not for other patented uses for which the brand-name drug is prescribed.
Let's personalize your content